

1. Record Nr.	UNINA9910809636003321
Titolo	Clinical aspects of psychopharmacology in childhood and adolescence / / Donald E. Greydanus ... [et al.], editors
Pubbl/distr/stampa	Hauppauge, NY, : Nova Science, c2011
ISBN	1-61122-715-1
Edizione	[1st ed.]
Descrizione fisica	1 online resource (280 p.)
Collana	Health and human development book series
Altri autori (Persone)	GreydanusDonald E
Disciplina	615/.780835
Soggetti	Pediatric psychopharmacology Adolescent psychopharmacology
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Intro -- CLINICAL ASPECTS OF PSYCHOPHARMACOLOGY IN CHILDHOOD AND ADOLESCENCE -- CLINICAL ASPECTS OF PSYCHOPHARMACOLOGY IN CHILDHOOD AND ADOLESCENCE -- Contents -- Foreword -- Introduction: pediatric psychopharmacology -- Modern psychopharmacology -- Conclusions -- References -- Section One: ADHD -- Chapter I Attention deficit hyperactivity disorder: pharmacologic management in children and adolescents -- Introduction -- Assessment and treatment principles -- Diagnostic criteria -- Diagnostic work up -- Comorbidity -- Discussing medications and monitoring with patients and caretakers -- Treatment planning and multimodal options -- Psychopharmacology of ADHD -- FDA approved stimulants -- Methylphenidate (MPH) preparations -- Oral short acting MPH formulations (3 - 5 hours duration) -- Multimodal treatment study of children with ADHD (MTA) study -- Preschool ADHD treatment study (pats) -- Other MPH IR formulations -- Oral intermediate acting MPH formulations (up to 8 hours duration) -- Long acting MPH formulations (up to 12 hours duration) -- MPH transdermal formulation (MTS) -- Amphetamine (AMP) preparations -- Short acting AMP formulations (up to 6 hours) -- Long acting AMP formulations (up to 8-10hHrs) -- Prodrug formulation -- Special safety considerations regarding stimulants -- Cardiovascular -- Growth -- Abuse potential -- Tics -- FDA approved non stimulants -- Atomoxetine (strattera) -- Guanfacine XRr (intuniv) -- Non FDA

approved treatments -- Monitoring tools -- ADHD pharmacotherapy  
FaQs -- Conclusions -- Acknowledgments -- References -- Chapter II  
Attention deficit hyperactivity disorder and comorbid substance abuse  
-- Introduction -- Epidemiology -- Patterns of prescription stimulant  
medications -- Can childhood ADHD contribute to adolescent  
substance abuse? -- Detecting comorbid ADHD and SUD -- Clinical  
considerations.

Minimizing risks -- Impact of treatment on course of sud -- ADHD  
medications with low abuse potential -- Behavioral treatments --  
Clinical management -- Conclusions -- References -- Section Two:  
Mental Health Aspects -- Chapter III Psychotherapy in the age of  
pharmacology -- Introduction -- A literature review --  
Pharmacotherapy -- Psychotherapy -- Conclusions -- References --  
Chapter IV Child and adolescent depression -- Introduction --  
Epidemiology -- Clinical features -- Comorbid conditions -- Treatment  
-- Conclusions -- References -- Chapter V Pediatric bipolar disorder  
-- Introduction -- Epidemiology -- Clinical features -- Comorbid  
conditions -- Treatment -- Medication management -- Acute-phase  
treatment -- Maintenance treatment -- Treatment of comorbid  
disorders -- Conclusion -- References -- Chapter VI Anxiety disorders  
in children and adolescents -- Introduction -- Epidemiology -- Clinical  
features -- Treatment -- Selective serotonin re-uptake inhibitors  
(SSRIs) -- SSRI adverse effects -- Serotonin and nor-epinephrine re-  
uptake inhibitors -- Benzodiazepines -- Tricyclic antidepressants --  
Buspirone -- Beta-blockers -- Hydroxyzine -- Mirtazepine and  
nefazodone -- Conclusions -- Acknowledgments -- References --  
Chapter VII Oppositional defiant and conduct disorders -- Introduction  
-- Epidemiology -- Clinical features -- Comorbid conditions --  
Treatment -- Non-medication treatments -- Medication treatments --  
Psychostimulants -- Atomoxetine -- Lithium -- Atypical antipsychotics  
(AAs) -- Non-lithium mood stabilizers -- Other medications --  
Conclusions -- References -- Chapter VIII Aggressive and violent  
behavior -- Introduction -- Epidemiology -- Clinical features --  
Comorbid conditions -- Rule-out medical disorders -- Rule-out  
substance use disorders (SUDs) -- Identify psychiatric disorders --  
Disruptive behavior disorders (DBDs).

Mood disorders -- Anxiety disorders -- Psychotic disorders -- Impulse  
control disorders -- Tic disorders -- Personality disorders --  
Treatment -- Conclusions -- References -- Chapter IX Tic disorders in  
children and adolescents -- Introduction -- Definitions --  
Epidemiology -- Differential diagnosis/comorbidity --  
Psychopharmacology of tic disorders -- Alpha agonists --  
Antipsychotics -- Dopamine receptor agonists -- Baclofen --  
Stimulants -- Antidepressants -- Anticonvulsants -- Others --  
Conclusions -- Acknowledgments -- References -- Section Three:  
Specific Disorders -- Chapter X Autistic spectrum disorders --  
Introduction -- Epidemiology -- Clinical features -- Etiology --  
Assessment -- Treatment -- Conclusions -- References -- Chapter XI  
Schizophrenia in children and adolescents -- Introduction --  
Epidemiology -- Clinical features -- Important considerations while  
diagnosing childhood schizophrenia -- Assessment -- Rating and  
diagnostic scales -- Comorbid conditions -- Treatment --  
Psychopharmacology -- Atypical antipsychotics -- Clozapine -- Typical  
Antipsychotics -- Depot injections of medication -- Psychosocial  
interventions -- Conclusion -- References -- Chapter XII Cognitive-  
adaptive disabilities -- Introduction -- Epidemiology -- Clinical  
features -- Comorbid conditions -- Mood disorders -- Anxiety  
disorders -- Attention-deficit/hyperactivity disorder (ADHD) --

Psychotic disorders -- Other disorders -- Treatment -- Mood disorders  
-- Bipolar disorder -- Anxiety disorders -- Attention-  
deficit/hyperactivity disorder -- Psychotic disorders -- Conclusions --  
References -- Section Four: Other Use -- Chapter XIII Substance abuse  
disorders in adolescents: pharmacologic management -- Introduction  
-- Alcohol -- Drug interactions -- Amphetamines -- Cocaine --  
Opioids -- Heroin dependence management -- Conclusions --  
Acknowledgments -- References.  
Chapter XIV Smoking cessation and pharmacological agents --  
Introduction -- Nicotine replacement therapy -- Nicotine inhaler --  
Nicotine gum -- Nicotine lozenge -- Nicotine nasal spray -- Nicotine  
patch -- Bupropion SR -- Varenicline -- Second-line medications --  
Clonidine -- Nortriptyline -- Conclusions -- References -- Chapter XV  
Sleep disorders in children and adolescents -- Introduction --  
Epidemiology -- Evaluation -- Insomnia -- Excessive daytime  
sleepiness -- Narcolepsy -- Klein-levin syndrome -- Parasomnias --  
Restless legs syndrome (RLS) -- Sleep disordered breathing --  
Conclusion -- Acknowledgments -- References -- Section Five:  
Conclusions -- Chapter XVI Pediatric psychopharmacology: where do  
we go from here? -- Introduction -- Pediatric psychopharmacology:  
quo vadis? -- Benefit of psychopharmacologic versus psychological  
therapies -- Benefit of psychopharmacology in pediatric mental illness  
-- Hope versus Hype of pharmaceutical companies' for-profit research  
-- Intervention of governments in research -- Impact of genetics on  
psychopharmacology -- Results of sleep research on pediatric mental  
health -- Training of primary care clinicians in mental health --  
Conclusions -- References -- Section Six: Acknowledgments --  
Chapter XVII About the editors -- Chapter XVIII About the Department  
of Pediatrics and Human Development, Michigan State University  
College of Human Medicine, MSU/Kalamazoo Center for Medical  
Studies, Kalamazoo, Michigan, United States -- Mission and service --  
Research activities -- Chapter XIX About the National Institute of Child  
Health and Human Development in Israel -- Mission -- Service and  
academic activities -- Research activities -- National collaboration --  
International collaboration -- Targets -- Chapter XX About the book  
series "Health and human development".  
Clinical aspects of psychopharmacology in childhood and adolescence  
-- Index -- Blank Page.

---